Micafungin Viatris (Micafungin)

Micafungin is an echinocandin antifungal that targets the fungal cell wall.

• Invasive candidiasis: effective in treating bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal infection of the esophagus caused by Candida species.
• Candidemia: clears Candida organisms from the blood stream.
• Prophylaxis in hematopoietic stem cell transplantation: prevents invasive fungal infections in transplant recipients.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical structural component of the fungal cell wall. By disrupting cell‑wall formation, the drug leads to osmotic instability and fungal cell death, while having minimal effect on human cells that lack this pathway.

Micafungin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Elevated liver enzymes: transient increase in ALT or AST.
• Fever: mild to moderate temperature rise.
• Nausea: occasional gastrointestinal discomfort.
• Headache: mild headache episodes.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury requiring monitoring.
• Hypersensitivity reactions: rash, pruritus, or anaphylaxis.
• Infusion‑related reactions: hypotension, dyspnea, or chest pain.
• Renal impairment: acute kidney injury in susceptible patients.

When prescribing Micafungin, clinicians should consider several precautionary measures to ensure safe use.

• Liver function monitoring: assess baseline transaminases and repeat during therapy.
• Renal function assessment: evaluate creatinine clearance before and during treatment.
• Drug interactions: review concomitant medications that affect hepatic metabolism.
• Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited.
• Pediatric use: adjust dosing based on weight and clinical condition; follow specialist guidance.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Cytochrome P450 inducers (e.g., rifampin, carbamazepine): may reduce micafungin exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase micafungin levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustment.
• Antifungal agents (e.g., azoles): overlapping toxicity, monitor liver function.
• Warfarin: potential alteration of anticoagulant effect, monitor INR.